The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis (Q35764862)

From Wikidata
Jump to navigation Jump to search
scientific article published on 20 May 2015
edit
Language Label Description Also known as
English
The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis
scientific article published on 20 May 2015

    Statements

    The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis (English)
    Maarten Van Roy
    Cedric Ververken
    Els Beirnaert
    Sven Hoefman
    Joost Kolkman
    Michel Vierboom
    Elia Breedveld
    Bert 't Hart
    Sofie Poelmans
    Lieselot Bontinck
    Alex Hemeryck
    Sandy Jacobs
    Judith Baumeister
    Hans Ulrichts

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit